Effect of metformin on left ventricular function after acute myocardial infarction in patients without diabetes: The GIPS-III randomized clinical trial

JAMA

Volumn 311, Issue 15, 2014, Pages 1526-1535

  Lexis, Chris P H ^a   Van Der Horst, Iwan C C ^a   Lipsic, Erik ^a   Wieringa, Wouter G ^a   De Boer, Rudolf A ^a   Van Den Heuvel, Ad F M ^a   Van Der Werf, Hindrik W ^a   Schurer, Remco A J ^a   Pundziute, Gabija ^a   Tan, Eng S ^a   Nieuwland, Wybe ^a   Willemsen, Hendrik M ^a   Dorhout, Bernard ^a   Molmans, Barbara H W ^a   Van Der Horst Schrivers, Anouk N A ^a   Wolffenbuttel, Bruce H R ^a   Ter Horst, Gert J ^a   Van Rossum, Albert C ^b   Tijssen, Jan G P ^c   Hillege, Hans L ^a   De Smet, Bart J G L ^d   Van Der Harst, Pim ^a   Van Veldhuisen, Dirk J ^a   more..

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d MEANDER MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; METFORMIN; PLACEBO;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CAUSE OF DEATH; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HEART REINFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TREATMENT DURATION;

AGED; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MAGNETIC RESONANCE IMAGING; MALE; METFORMIN; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 84898607351     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.3315     Document Type: Article

References (38)

1. Steg PG, James SK, Atar D, et al; Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). ESC Guidelines for the management of acutemyocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33(20):2569-2619.
2. O'Gara PT, Kushner FG, Ascheim DD, et al American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions. 2013 ACCF/AHA guideline for the management of ST-elevationmyocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61(4):e78-e140.
3. Patel MR, Dehmer GJ, Hirshfeld JW, Smith PK, Spertus JA. ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Appropriateness Criteria for Coronary Revascularization: a report of the American College of Cardiology Foundation Appropriateness Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, and the American Society of Nuclear Cardiology: endorsed by the American Society of Echocardiography, the Heart Failure Society of America, and the Society of Cardiovascular Computed Tomography. Circulation. 2009;119(9):1330-1352.
4. Terkelsen CJ, Sørensen JT, Maeng M, et al. System delay and mortality among patients with STEMI treated with primary percutaneous coronary intervention. JAMA. 2010;304(7):763-771.
5. Pinto DS, Frederick PD, Chakrabarti AK, et al National Registry of Myocardial Infarction Investigators. Benefit of transferring ST-segment-elevationmyocardial infarction patients for percutaneous coronary intervention compared with administration of onsite fibrinolytic declines as delays increase. Circulation. 2011;124(23):2512-2521.
6. Velagaleti RS, Pencina MJ, Murabito JM, et al. Long-term trends in the incidence of heart failure aftermyocardial infarction. Circulation. 2008;118(20):2057-2062.
7. Weir RA, McMurray JJ, Velazquez EJ. Epidemiology of heart failure and left ventricular systolic dysfunction after acutemyocardial infarction: prevalence, clinical characteristics, and prognostic importance. Am J Cardiol. 2006;97(10A):13F-25F.
8. Steg PG, Dabbous OH, Feldman LJ, et al Global Registry of Acute Coronary Events Investigators. Determinants and prognostic impact of heart failure complicating acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE). Circulation. 2004;109(4):494-499. (Pubitemid 38168512)
9. McAlister FA, Quan H, Fong A, Jin Y, Cujec B, Johnson D. Effect of invasive coronary revascularization in acutemyocardial infarction on subsequent death rate and frequency of chronic heart failure. Am J Cardiol. 2008;102(1):1-5.
10. Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347(18):1397-1402. (Pubitemid 35239711)
11. Lexis CP, van der Horst IC, Lipsic E, et al GIPS-III Investigators. Metformin in non-diabetic patients presenting with ST elevationmyocardial infarction: rationale and design of the glycometabolic intervention as adjunct to primary percutaneous intervention in ST elevationmyocardial infarction (GIPS)-III trial. Cardiovasc Drugs Ther. 2012;26(5):417-426.
12. El Messaoudi S, Rongen GA, de Boer RA, Riksen NP. The cardioprotective effects of metformin. Curr Opin Lipidol. 2011;22(6):445-453.
13. Yin M, van der Horst IC, van Melle JP, et al. Metformin improves cardiac function in a nondiabetic rat model of post-MI heart failure. Am J Physiol Heart Circ Physiol. 2011;301(2):H459-H468.
14. Gundewar S, Calvert JW, Jha S, et al. Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. Circ Res. 2009;104(3):403-411.
15. Calvert JW, Gundewar S, Jha S, et al. Acute metformin therapy confers cardioprotection againstmyocardial infarction via AMPK-eNOS-mediated signaling. Diabetes. 2008;57(3):696-705.
16. Mellbin LG, Malmberg K, Norhammar A, Wedel H, Rydén L; DIGAMI 2 Investigators. The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. Eur Heart J. 2008;29(2):166-176.
17. Mellbin LG, Malmberg K, Norhammar A, Wedel H, Rydén L; DIGAMI 2 Investigators. Prognostic implications of glucose-lowering treatment in patients with acutemyocardial infarction and diabetes: experiences from an extended follow-up of the Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 2 Study. Diabetologia. 2011;54(6):1308-1317.
18. Lexis CP, Wieringa WG, Hiemstra B, et al. Chronicmetformin treatment is associated with reduced myocardial infarct size in diabetic patients with ST-segment elevationmyocardial infarction. Cardiovasc Drugs Ther. 2014;28(2):163-171.
19. Pokorney SD, Rodriguez JF, Ortiz JT, Lee DC, Bonow RO, Wu E. Infarct healing is a dynamic process following acutemyocardial infarction. J Cardiovasc Magn Reson. 2012;14:62.
20. van Veldhuisen DJ, Linssen GC, Jaarsma T, et al. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J Am Coll Cardiol. 2013;61(14):1498-1506.
21. Doughty RN, Whalley GA, Walsh HA, Gamble GD, López-Sendón J, Sharpe N; CAPRICORN Echo Substudy Investigators. Effects of carvedilol on left ventricular remodeling after acutemyocardial infarction: the CAPRICORN Echo Substudy. Circulation. 2004;109(2):201-206. (Pubitemid 38114140)
22. Sharpe N, Smith H, Murphy J, Greaves S, Hart H, Gamble G. Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin-converting-enzyme inhibition. Lancet. 1991;337(8746):872-876.
23. Hirsch A, Nijveldt R, van der Vleuten PA, et al HEBE Investigators. Intracoronary infusion of mononuclear cells from bone marrow or peripheral blood compared with standard therapy in patients after acutemyocardial infarction treated by primary percutaneous coronary intervention: results of the randomized controlled HEBE trial. Eur Heart J. 2011;32(14):1736-1747.
24. Inzucchi SE, Bergenstal RM, Buse JB, et al American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364-1379.
25. Tucker GT, Casey C, Phillips PJ, Connor H, Ward JD, Woods HF. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol. 1981;12(2):235-246. (Pubitemid 11034446)
26. Gersh BJ, Stone GW, White HD, Holmes DR Jr. Pharmacological facilitation of primary percutaneous coronary intervention for acute myocardial infarction: is the slope of the curve the shape of the future? JAMA. 2005;293(8):979-986. (Pubitemid 40271130)
27. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854-865.
28. Kao J, Tobis J, McClelland RL, et al Investigators in the Prevention of Restenosis With Tranilast and Its Outcomes Trial. Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous intervention. Am J Cardiol. 2004;93(11):1347-1350. (Pubitemid 38692459)
29. Roussel R, Travert F, Pasquet B, et al Reduction of Atherothrombosis for Continued Health (REACH) Registry Investigators. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med. 2010;170(21):1892-1899.
30. Li J, Xu JP, Zhao XZ, Sun XJ, Xu ZW, Song SJ. Protective effect ofmetformin on myocardial injury in metabolic syndrome patients following percutaneous coronary intervention. Cardiology. 2014;127(2):133-139.
31. Rydén L, Grant PJ, Anker SD, et al Authors/Task Force Members; ESC Committee for Practice Guidelines (CPG); Document Reviewers. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 2013;34(39):3035-3087.
32. Renda F, Mura P, Finco G, Ferrazin F, Pani L, Landoni G. Metformin-associated lactic acidosis requiring hospitalization: a national 10 year survey and a systematic literature review. Eur Rev Med Pharmacol Sci. 2013;17(suppl 1):45-49.
33. Maioli M, Toso A, Leoncini M, Gallopin M, Musilli N, Bellandi F. Persistent renal damage after contrast-induced acute kidney injury: incidence, evolution, risk factors, and prognosis. Circulation. 2012;125(25):3099-3107.
34. Preiss D, Lloyd SM, Ford I, et al.Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial. Lancet Diabetes Endocrinol. 2014;2(2):116-124.
35. Merlotti C, Morabito A, Pontiroli AE. Prevention of type 2 diabetes: a systemic review and meta-analysis of different intervention strategies [published online January 29, 2014]. Diabetes Obes Metab. doi:10.1111/dom.12270.
36. El Aidi H, Adams A, Moons KG, et al. Cardiac magnetic resonance imaging findings and the risk of cardiovascular events in patients with recent myocardial infarction or suspected or known coronary artery disease-a systematic review of prognostic studies. J Am Coll Cardiol. 2014;63(11):1031-1045.
37. Scirica BM, Kadakia MB, de Lemos JA, et al National Cardiovascular Data Registry. Association between natriuretic peptides and mortality among patients admitted with myocardial infarction: a report from the ACTION Registry(R)-GWTG™. Clin Chem. 2013;59(8):1205-1214.
38. Luchner A, Hengstenberg C, Löwel H, et al. NT-ProBNP in outpatients after myocardial infarction: interaction between symptoms and left ventricular function and optimized cut-points. J Card Fail. 2005;11(5)(suppl):S21-S27.